UBS Group Cuts Bio-Rad Laboratories (NYSE:BIO) Price Target to $310.00
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) had its target price reduced by UBS Group from $355.00 to $310.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. UBS Group’s price target points to a potential upside of 30.90% from the company’s current […]
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) had its target price reduced by UBS Group from $355.00 to $310.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. UBS Group’s price target points to a potential upside of 30.90% from the company’s current […]
